Remove 2015 Remove FDA Approval Remove Pharmaceuticals
article thumbnail

FDA Approves First Generic of Symbicort to Treat Asthma and COPD

The Pharma Data

To further facilitate generic drug development, and to assist the generic pharmaceutical industry in this process, the FDA publishes product-specific guidances (PSGs) describing the agency’s current thinking and expectations on how to develop generic drug products that are therapeutically equivalent to their brand name counterparts.

article thumbnail

Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy

The Pharma Data

Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel for advanced or recurrent endometrial cancer patients. FDA approval of the VENTANA MMR RxDx Panel provides clinicians with access to a fully automated, easy-to-use MMR test to identify patients who are eligible for therapy with JEMPERLI.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Standigm and SK Chemicals Repurpose FDA-approved Drug into Rheumatoid Arthritis Candidate and Apply for Patent through their Open Innovation Partnership

The Pharma Data

Founded in 2015, Standigm has raised $23M from leading investors and developed an elite team with multi-disciplinary expertise in chemistry, biology, pharmacology, artificial intelligence, and data structures to ease the pains of patients all over the world.

article thumbnail

Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA

The Pharma Data

“By committing to bring biosimilar formulations such as Hyrimoz citrate-free HCF to patients, we are serving a critical need in expanding access to important medicines and fueling pharmaceutical innovation.”. The adalimumab reference medicine (Humira ®* ) was first approved with an adalimumab concentration of 50 mg/mL.

article thumbnail

The genetic modifier approach: identifying the right target for rare diseases

Drug Target Review

4 For the treatment of rare genetic disorders especially, drugs with genetically supported targets are more than twice as likely to be approved 5 , thereby indicating genetics and genomics can empower companies to develop better drugs. Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs. Epub 2015 Nov 12.

Disease 111
article thumbnail

Announcing the first biopharma IPNFT Transaction

Molecule Blog

Announcing the first biopharma IP-NFT Transaction Funding the first longevity research project by utilizing intellectual property NFTs in the pharmaceutical space Summary The vote has passed, the decision is made: The Scheibye-Knudsen Lab will be the first research organisation to fund their longevity research via an IPNFT.

article thumbnail

Another Milestone in the Cystic Fibrosis Journey

NIH Director's Blog: Drug Development

According to preliminary data from one Phase 1 and two Phase 2 clinical trials reported by Vertex Pharmaceuticals Inc., The first major advance in molecularly targeted drug treatment for the disease came in 2012, when the Food and Drug Administration (FDA) approved ivacaftor (Kalydeco). About 30,000 Americans have CF.